Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Cathepsin K inhibitors designed at SB for bone and cartilage disorders

June 30, 2000

Axokine phase I results reported at ENDO 2000 meeting

June 30, 2000

FDA approves first drug to treat growth failure in children with Prader-Willi syndrome

June 30, 2000

Nutropin Depot now available

June 29, 2000

Aventis receives E.U. approval for Lantus

June 29, 2000

Eniporide now claimed to be useful in NIDDM

June 29, 2000

ENDO 2000: focus on cardiovascular effects of examorelin

June 29, 2000

NitroMed and UT report phase II results of NMI-870 as treatment for female sexual dysfunction

June 29, 2000

AndroGel now available in U.S. to treat men with hypogonadism

June 28, 2000

JTT-608 stimulates GLP-1 secretion from the intestine, similar to glucose

June 28, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...